Consensus Cardinal Health, Inc.

Stocks

CAH

US14149Y1082

Pharmaceuticals

Market Closed - NYSE 00:00:02 08/10/2026 +04			5-day change	1st Jan Change
232.16 ^USD	-0.55%		+4.34%	+12.97%

10-01	Cardinal Health renews contract with CVS Health
10-01	Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health	CI

Evolution of the Average Target: Cardinal Health, Inc.

Evolution of the Target Price: Cardinal Health, Inc.

Changes in Analyst Recommendations: Cardinal Health, Inc.

499518b3862ba28.7t4aRfGPltfoQ5z4mlwESwMy9Bd_Dpp-khjqc9qKhaw.2JZ-dKm7pLCsM-y72Q1CfXJAl3s4bf4Uw1eGCY7B___D81I8mubglY8UrA~328bd2e185851b32e359cef4cbd120e3

Analysts' recommendations: Cardinal Health, Inc.

10-01	Evercore ISI Adjusts PT on Cardinal Health to $270 From $265, Maintains Outperform Rating	MT
08-19	Cardinal Health's Integration of Higher-Margin Services Will Drive Outperformance, RBC Says	MT
08-19	RBC Initiates Cardinal Health at Outperform With $276 Price Target	MT
08-13	Evercore ISI Adjusts Cardinal Health PT to $270 From $265, Maintains Outperform Rating	MT
08-13	TD Cowen Adjusts Cardinal Health Price Target to $280 From $275, Maintains Buy Rating	MT
08-13	JPMorgan Adjusts Cardinal Health Price Target to $260 From $215, Maintains Neutral Rating	MT
08-13	Deutsche Bank Adjusts Cardinal Health Price Target to $261 From $223, Maintains Hold Rating	MT
08-12	Barclays Adjusts Cardinal Health Price Target to $275 From $258, Maintains Overweight Rating	MT
08-12	Evercore ISI Adjusts PT on Cardinal Health to $265 From $270, Maintains Outperform Rating	MT
08-12	UBS Adjusts Price Target on Cardinal Health to $280 From $274, Keeps Buy Rating	MT
08-12	Jefferies Adjusts Price Target on Cardinal Health to $280 From $270, Maintains Buy Rating	MT
08-12	Wells Fargo Adjusts Cardinal Health Price Target to $277 From $245, Maintains Overweight Rating	MT
08-12	Citigroup Adjusts Cardinal Health Price Target to $280 From $265, Maintains Buy Rating	MT
08-12	Leerink Partners Adjusts Cardinal Health PT to $292 From $275, Maintains Outperform Rating	MT
08-12	Evercore ISI Adjusts Cardinal Health PT to $270 From $265, Maintains Outperform Rating	MT
08-12	Mizuho Securities Adjusts Cardinal Health PT to $250 From $240, Maintains Outperform Rating	MT
08-12	Baird Adjusts Cardinal Health Price Target to $274 From $251, Maintains Outperform Rating	MT
08-12	Morgan Stanley Adjusts PT on Cardinal Health to $265 From $255, Keeps Overweight Rating	MT
07-23	Mizuho Adjusts Price Target on Cardinal Health to $240 From $235, Maintains Outperform Rating	MT
07-23	Citigroup Adjusts Price Target on Cardinal Health to $265 From $245, Maintains Buy Rating	MT
07-22	Baird Adjusts Price Target on Cardinal Health to $251 From $248, Maintains Outperform Rating	MT
07-20	UBS Adjusts Price Target on Cardinal Health to $274 From $260, Maintains Buy Rating	MT
07-09	TD Cowen Adjusts Price Target on Cardinal Health to $275 From $255	MT
07-07	Evercore ISI Adjusts Price Target on Cardinal Health to $265 From $240	MT
07-02	BofA Securities Adjusts Cardinal Health Price Target to $260 From $240	MT

More recommendations

Pharmaceuticals Wholesale

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CARDINAL HEALTH, INC.					+16.44%
	ELI LILLY AND COMPANY					+11.82%
	JOHNSON & JOHNSON					+8.2%
	ABBVIE INC.					+3.47%
	MERCK & CO., INC.					+9.45%
	ROCHE HOLDING AG					+4.35%
	NOVARTIS AG					+4.69%
	ASTRAZENECA PLC					+30.29%
	AMGEN INC.					-5.23%
	GILEAD SCIENCES, INC.					+8.46%
	Average					+9.19%
	Weighted average by Cap.					+8.91%